Vlahov IR - Search Results

1

In vivo structural activity and optimization studies of folate-tubulysin conjugates.

Reddy JA, Dorton R, Dawson A, Vetzel M, Parker N, Nicoson JS, Westrick E, Klein PJ, Wang Y, Vlahov IR, Leamon CP. Reddy JA, et al. Among authors: vlahov ir. Mol Pharm. 2009 Sep-Oct;6(5):1518-25. doi: 10.1021/mp900086w. Mol Pharm. 2009. PMID: 19630399

2

Folate receptor specific anti-tumor activity of folate-mitomycin conjugates.

Reddy JA, Westrick E, Vlahov I, Howard SJ, Santhapuram HK, Leamon CP. Reddy JA, et al. Cancer Chemother Pharmacol. 2006 Aug;58(2):229-36. doi: 10.1007/s00280-005-0151-z. Epub 2005 Dec 6. Cancer Chemother Pharmacol. 2006. PMID: 16331500

3

Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.

Reddy JA, Westrick E, Santhapuram HK, Howard SJ, Miller ML, Vetzel M, Vlahov I, Chari RV, Goldmacher VS, Leamon CP. Reddy JA, et al. Cancer Res. 2007 Jul 1;67(13):6376-82. doi: 10.1158/0008-5472.CAN-06-3894. Cancer Res. 2007. PMID: 17616697

4

Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential.

Lu Y, You F, Vlahov I, Westrick E, Fan M, Low PS, Leamon CP. Lu Y, et al. Mol Pharm. 2007 Sep-Oct;4(5):695-706. doi: 10.1021/mp070050b. Epub 2007 Sep 5. Mol Pharm. 2007. PMID: 17784727

5

Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.

Leamon CP, Reddy JA, Vetzel M, Dorton R, Westrick E, Parker N, Wang Y, Vlahov I. Leamon CP, et al. Cancer Res. 2008 Dec 1;68(23):9839-44. doi: 10.1158/0008-5472.CAN-08-2341. Cancer Res. 2008. PMID: 19047164

6

Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical.

Leamon CP, Parker MA, Vlahov IR, Xu LC, Reddy JA, Vetzel M, Douglas N. Leamon CP, et al. Among authors: vlahov ir. Bioconjug Chem. 2002 Nov-Dec;13(6):1200-10. doi: 10.1021/bc0200430. Bioconjug Chem. 2002. PMID: 12440854

7

Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic.

Leamon CP, Reddy JA, Vlahov IR, Vetzel M, Parker N, Nicoson JS, Xu LC, Westrick E. Leamon CP, et al. Among authors: vlahov ir. Bioconjug Chem. 2005 Jul-Aug;16(4):803-11. doi: 10.1021/bc049709b. Bioconjug Chem. 2005. PMID: 16029021

8

Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate.

Leamon CP, Reddy JA, Vlahov IR, Kleindl PJ, Vetzel M, Westrick E. Leamon CP, et al. Among authors: vlahov ir. Bioconjug Chem. 2006 Sep-Oct;17(5):1226-32. doi: 10.1021/bc060145g. Bioconjug Chem. 2006. PMID: 16984132

9

Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.

Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, Vetzel M, Kleindl P, Vlahov IR, Leamon CP. Reddy JA, et al. Among authors: vlahov ir. Cancer Res. 2007 May 1;67(9):4434-42. doi: 10.1158/0008-5472.CAN-07-0033. Cancer Res. 2007. PMID: 17483358

10

Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.

Leamon CP, Reddy JA, Vlahov IR, Westrick E, Parker N, Nicoson JS, Vetzel M. Leamon CP, et al. Among authors: vlahov ir. Int J Cancer. 2007 Oct 1;121(7):1585-92. doi: 10.1002/ijc.22853. Int J Cancer. 2007. PMID: 17551919

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47 results

Search Page

Filters